# US 2018/0022704 A1 · Process for the preparation of histamine h3 receptor modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022704 A1
- Document ID: US20180022704A1
- Status: Published application
- Kind: A1
- Application number: 15/724,711
- Filed: 2017-10-04
- Published: 2018-01-25
- Earliest claimed: 2009-03-18
- Assignees: Janssen Pharmaceutica NV
- Applicants: Janssen Pharmaceutica NV
- Inventors: Diego Fernando Domenico BROGGINI; Vit LELLEK; Susanne LOCHNER; Neelakandha S. MANI; Adrian MAURER; Daniel J. PIPPEL; Lana K. YOUNG
- Web page: https://patentgrep.com/patent/US20180022704A1

## CPC

- C07D 213/82: in position 3
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention is directed to novel processes for the preparation of histamine H3 receptor modulators, in the treatment of for example, cognitive disorders, sleep disorders and/or psychiatric disorders.

## Claims

### Claim 1

A process for the preparation of a compound of formula (I)
wherein
R1 is selected from the group consisting of C1-4alkyl and C3-10cycloalkyl;
m is an integer from 1 to 2;
R2 is selected from the group consisting of —OCHR3R4 and —Z—Ar;
R3 is hydrogen and R4 is a C3-10cycloalkyl or heterocycloalkyl ring; wherein the C3-10cycloalkyl or the heterocycloalkyl ring is unsubstituted or substituted with —C1-4alkyl or acetyl;
alternatively, R3 and R4 are taken together with the carbon to which they are attached to form a C3-10cycloalkyl or heterocycloalkyl ring; wherein the C3-10cycloalkyl or the heterocycloalkyl ring is unsubstituted or substituted with —C1-4alkyl or acetyl;
Z is selected from the group consisting of S and O;
Ar is a phenyl or heteroaryl; wherein the phenyl or heteroaryl is unsubstituted or substituted with one, two, or three R5 substituents; wherein each R5 substituent is independently selected from the group consisting of halogen, —C1-4alkyl, —OH, —OC1-4alkyl, —SC1-4alkyl, —CN, —CONRaRb, and —NO2; and wherein Ra and Rb are each independently —H or —C1-4alkyl;
or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof; comprising
reacting a compound of formula (V) with a compound of formula (VI), wherein LG1 is a first leaving group and LG2 is a second leaving group, in the presence of a base, in an organic solvent; to yield the corresponding compound of formula (VII);
reacting the compound of formula (VII) with an aldehyde or ketone derivative of the desired R1 substituent group; in the presence of a reducing agent; in an organic solvent; to yield the corresponding compound of formula (X);
reacting the compound of formula (X) with a compound of formula (XII); in the presence of a first inorganic base; in an organic solvent; or
reacting the compound of formula (X) with a compound of formula (XIII); in the presence of a second inorganic base; in an organic solvent;
to yield the corresponding compound of formula (I).

### Claim 2 (depends on 1)

A process as in claim 1, wherein R1 is cyclobutyl, m is 1 and R2 is selected from the group consisting of 4-fluorophenyl, 3-cyanophenyl, 4-tetrahydropyranyl, LG1 is chloro and LG2 is chloro.

### Claim 3

A process for the preparation of a compound of formula (I-E)
wherein
R1 is selected from the group consisting of C1-4alkyl and C3-10cycloalkyl;
m is 2
R2 is selected from the group consisting of —OCHR3R4 and —Z—Ar;
R3 is hydrogen and R4 is a C3-10cycloalkyl or heterocycloalkyl ring; wherein the C3-10cycloalkyl or the heterocycloalkyl ring is unsubstituted or substituted with —C1-4alkyl or acetyl;
alternatively, R3 and R4 are taken together with the carbon to which they are attached to form a C3-10cycloalkyl or heterocycloalkyl ring; wherein the C3-10cycloalkyl or the heterocycloalkyl ring is unsubstituted or substituted with —C1-4alkyl or acetyl;
Z is selected from the group consisting of S and O;
Ar is a phenyl or heteroaryl; wherein the phenyl or heteroaryl is unsubstituted or substituted with one, two, or three R5 substituents; wherein each R5 substituent is independently selected from the group consisting of halogen, —C1-4alkyl, —OH, —OC1-4alkyl, —SC1-4alkyl, —CN, —CONRaRb, and —NO2; and wherein Ra and Rb are each independently —H or —C1-4alkyl;
or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof; comprising
reacting a compound of formula (V-S) with an aldehyde or ketone derivative of the desired R1 substituent group; neat or in an organic solvent; to yield the corresponding compound of formula (IX);
reacting the compound of formula (IX) with a reducing agent; neat, in water or in an aqueous organic solvent; to yield the corresponding compound of formula (XI);
reacting the compound of formula (XI) with a compound of formula (VI), wherein LG1 is a first leaving group and LG2 is a second leaving group; in an organic solvent;
alternatively reacting the compound of formula (XI) with a compound of formula (VI) wherein LG1 is a first leaving group and LG2 is a second leaving group; in the presence of a base; in a mixture of water and an organic solvent;
to yield the corresponding compound of formula (X-E)
reacting the compound of formula (X-E) with a compound of formula (XII); in the presence of a first inorganic base; in an organic solvent; or
reacting the compound of formula (X-E) with a compound of formula (XIII); in the presence of a second inorganic base; in an organic solvent;
to yield the corresponding compound of formula (I-E).

### Claim 4 (depends on 3)

A process as in claim 3, wherein R1 is cyclobutyl, m is 1 and R2 is selected from the group consisting of 4-fluorophenyl, 3-cyanophenyl, 4-tetrahydropyranyl, LG1 is chloro and LG2 is chloro.

### Claim 5

A process for the preparation of a compound of formula (I-E)
wherein
R1 is selected from the group consisting of C1-4alkyl and C3-10cycloalkyl;
m is 2
R2 is selected from the group consisting of —OCHR3R4 and —Z—Ar;
R3 is hydrogen and R4 is a C3-10cycloalkyl or heterocycloalkyl ring; wherein the C3-10cycloalkyl or the heterocycloalkyl ring is unsubstituted or substituted with —C1-4alkyl or acetyl;
alternatively, R3 and R4 are taken together with the carbon to which they are attached to form a C3-10cycloalkyl or heterocycloalkyl ring; wherein the C3-10cycloalkyl or the heterocycloalkyl ring is unsubstituted or substituted with —C1-4alkyl or acetyl;
Z is selected from the group consisting of S and O;
Ar is a phenyl or heteroaryl; wherein the phenyl or heteroaryl is unsubstituted or substituted with one, two, or three R5 substituents; wherein each R5 substituent is independently selected from the group consisting of halogen, —C1-4alkyl, —OH, —OC1-4alkyl, —SC1-4alkyl, —CN, —CONRaRb, and —NO2; and wherein Ra and Rb are each independently —H or —C1-4alkyl;
or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof; comprising
reacting a compound of formula (V-S) with an aldehyde or ketone derivative of the desired R1 substituent group; neat or in an organic solvent; to yield the corresponding compound of formula (IX);
reacting the compound of formula (IX) with a compound of formula (VI), wherein LG1 is a first leaving group and LG2 is a leaving group; in the presence of a reducing agent; in an organic solvent; to yield the corresponding compound of formula (X-E)
reacting the compound of formula (X-E) with a compound of formula (XII); in the presence of a first inorganic base; in an organic solvent; or
reacting the compound of formula (X-E) with a compound of formula (XIII); in the presence of a second inorganic base; in an organic solvent; to yield the corresponding compound of formula (I-E).

### Claim 6 (depends on 5)

A process as in claim 5, wherein R1 is cyclobutyl, m is 1 and R2 is selected from the group consisting of 4-fluorophenyl, 3-cyanophenyl, 4-tetrahydropyranyl, LG1 is chloro and LG2 is chloro.

### Claim 7

A process for the preparation of compound (I-C)
or a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutically active metabolite thereof; comprising
reacting a compound of formula (V-S) with a compound of formula (VIII-S), neat or in an organic solvent; to yield the corresponding compound of formula (IX-S);
reacting the compound of formula (IX-S) with a reducing agent; neat, in water or in an organic solvent; to yield the corresponding compound of formula (XI-S);
reacting the compound of formula (XI-S) with a compound of formula (VI-S), wherein LG1 is a first leaving group and LG2 is a second leaving group; in an organic solvent;
alternatively, reacting the compound of formula (XI-S) with a compound of formula (VI-S), wherein LG1 is a first leaving group and LG2 is a second leaving group; in the presence of a base; in a mixture of water and an organic solvent;
to yield the corresponding compound of formula (X-S);
reacting the compound of formula (X-S) with a compound of formula (XII-C); in the presence of a second inorganic base; in an organic solvent; to yield the corresponding compound (I-C).

### Claim 8 (depends on 7)

A process as in claim 7, wherein the compound of formula (VIII-S) is present in an amount in the range of from about 1.0 to about 1.5 molar equivalents.

### Claim 9 (depends on 8)

A process as in claim 8, wherein the compound of formula (VIII-S) is present in an amount of about 1.05 molar equivalents.

### Claim 10 (depends on 7)

A process as in claim 7, wherein the compound of formula (V-S) is reacted with the compound of formula (VIII-S) in an organic solvent and wherein the organic solvent is toluene.

### Claim 11 (depends on 7)

A process as in claim 7, wherein the compound of formula (V-S) is reacted with the compound of formula (VIII-S) at a temperature of about reflux temperature.

### Claim 12 (depends on 7)

A process as in claim 7, wherein the compound of formula (IX-S) is reacted with the reducing agent in the presence of an acid.

### Claim 13 (depends on 12)

A process as in claim 12, wherein the acid is hydrochloric acid and is present in an amount in the range of from about 3.0 to about 5.0 molar equivalents.

### Claim 14 (depends on 7)

A process as in claim 7, wherein the reducing agent is added as a solution in water, stabilized with sodium hydroxide in an amount of about 0.1 molar equivalents.

### Claim 15 (depends on 7)

A process as in claim 7, wherein the reducing agent is sodium borohydride.

### Claim 16 (depends on 15)

A process as in claim 15, wherein the sodium borohydride is present in an amount in the range of from about 0.5 to about 1.5 molar equivalents.

### Claim 17 (depends on 7)

A process as in claim 7, wherein the compound of formula (IX-S) is reacted with the reducing agent at a temperature in the range of from about −10° C. to about 0° C.

### Claim 18 (depends on 7)

A process as in claim 7, wherein the compound of formula (VI-S) LG1 and LG2 are each chloro.

### Claim 19 (depends on 7)

A process as in claim 7, wherein the compound of formula (VI-S) is present in an amount in the range of from about 1.0 to abut 1.5 molar equivalents.

### Claim 20 (depends on 19)

A process as in claim 19, wherein the compound of formula (VI-S) is present in an amount of about 1.05 molar equivalents.

### Claim 21 (depends on 7)

A process as in claim 7, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-S) in an organic solvent selected from the group consisting of methyl t-butyl ether, toluene and 2-methyl-THF.

### Claim 22 (depends on 7)

A process as in claim 7, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-S) at a temperature in the range of from about 0° C. to about 35° C.

### Claim 23 (depends on 7)

A process as in claim 7, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-S) in the presence of a base; wherein the base is sodium hydroxide; and wherein the sodium hydroxide is present in an amount in the range of from about 1.05 to about 1.2 molar equivalents.

### Claim 24 (depends on 7)

A process as in claim 7, wherein the compound of formula (VI-S) in MTBE is reacted with the compound of formula (XI-S) in water, in the presence of 30% NaOH, at a temperature in the range of from about 10° C. to about 15° C.

### Claim 25 (depends on 7)

A process as in claim 7, wherein the compound of formula (XII-C) is present in an amount in the range of from about 1.1 to about 1.5 molar equivalents.

### Claim 26 (depends on 7)

A process as in claim 7, wherein the second inorganic base is potassium hydroxide.

### Claim 27 (depends on 26)

A process as in claim 26, wherein the potassium hydroxide is present in an amount in the range of from about 2.0 to about 4.0 molar equivalents.

### Claim 28 (depends on 7)

A process as in claim 7, wherein the compound of formula (X-S) is reacted with the compound of formula (XII-A) in an organic solvent selected from the group consisting of toluene, acetonitrile and a mixture of toluene and water.

### Claim 29 (depends on 7)

A process as in claim 7, wherein the compound of formula (X-S) is reacted with the compound of formula (XII-C) at about reflux temperature.

### Claim 30 (depends on 7)

A process as in claim 7, wherein LG2 is chloro and wherein the compound of formula (X-S) is prepared as its corresponding HCl salt.

### Claim 31 (depends on 30)

A process as in claim 30, wherein the compound of formula (X-S) as its corresponding HCl salt is reacted with a first inorganic base prior to reacting with compound of formula (XII-C).

### Claim 32 (depends on 31)

A process as in claim 31, wherein the first inorganic base is sodium carbonate.

### Claim 33 (depends on 32)

A process as in claim 32, wherein the sodium carbonate is present in an amount sufficient to liberate the compound of formula (X-S) as a free base.

### Claim 34 (depends on 32)

A process as in claim 32, wherein the sodium carbonate is present in an amount of about 1.5 molar equivalents.

### Claim 35

A process for the preparation of a compound of formula (X-S)
wherein LG1 is a first leaving group; comprising
reacting a compound of formula (V-S) with a compound of formula (VIII-S), neat or in an organic solvent; to yield the corresponding compound of formula (IX-S);
reacting the compound of formula (IX-S) with a reducing agent; neat, in water or in an organic solvent; to yield the corresponding compound of formula (XI-S);
reacting the compound of formula (XI-S) with a compound of formula (VI-S), wherein LG2 is a second leaving group; in an organic solvent;
alternatively reacting the compound of formula (XI-S) with a compound of formula (VI-S), wherein LG2 is a second leaving group; in the presence of a base; in a mixture of water and an organic solvent;
to yield the corresponding compound of formula (X-S).

### Claim 36 (depends on 35)

A process as in claim 35, wherein LG1 is chloro.

### Claim 37 (depends on 35)

A process as in claim 35, wherein the compound of formula (VIII-S) is present in an amount in the range of from about 1.0 to about 1.5 molar equivalents.

### Claim 38 (depends on 35)

A process as in claim 35, wherein the compound of formula (V-S) is reacted with the compound of formula (VIII-S) in toluene, at a temperature greater than about 40° C.

### Claim 39 (depends on 35)

A process as in claim 35, wherein the compound of formula (IX-S) is reacted with the reducing agent in the presence an acid; wherein the acid is hydrochloric acid; and wherein the hydrochloric acid is present in an amount in the range of from about 3.0 to about 5.0 molar equivalents.

### Claim 40 (depends on 35)

A process as in claim 35, wherein the reducing agent is sodium borohydride and wherein the reducing agent is added as a solution in water, stabilized with about 0.1 molar equivalents of sodium hydroxide.

### Claim 41 (depends on 35)

A process as in claim 35, wherein the compound of formula (IX-S) is reacted at a temperature in the range of from about −10° C. to about 0° C.

### Claim 42 (depends on 35)

A process as in claim 35, wherein LG2 is chloro; wherein the compound of formula (VI-S) is present in an amount in the range of from about 1.0 to about 1.5 molar equivalents; and wherein the compound of formula (X-S) is prepared as its corresponding HCl salt.

### Claim 43 (depends on 35)

A process as in claim 35, wherein the compound of formula (XI-S) is reacted with the compound of formula (VI-S) in an organic solvent selected from the group consisting of toluene and 2-methyl-THF; and at a temperature in the range of form about room temperature to about 35° C.

### Claim 44 (depends on 35)

A process as in claim 35, wherein the compound of formula (XI-S) in water is reacted with a compound of formula (VI-S) in MTBE, in the presence of a base; wherein the base is 30% NaOH; at a temperature in the range of from about 10° C. to about 15° C.

### Claim 45

A crystalline form of a HCl salt of compound (I-C)

### Claim 46

A crystalline form of a HCl salt of compound (I-C)
comprising the following powder X-ray diffraction peaks:
Position [°2θ]
d-spacing [Å]
8.13
10.87
14.76
6.00
15.66
5.66
16.28
5.44
17.71
5.01
18.06
4.91
19.20
4.62
19.62
4.52
21.88
4.06
23.35
3.81
24.40
3.65
24.67
3.61
26.36
3.38
29.46
3.03
31.60
2.83

### Claim 47 (depends on 46)

A process for the preparation of the crystalline form of the HCl salt of compound (I-C) as in claim 46, comprising reacting compound (I-C) with anhydrous HCl acid in isopropanol.
